Home > Journals > Medicine > Bulletin du cancer > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Bulletin du Cancer
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer


Bulletin du Cancer. Volume 92, Number 4, 10039-44, Avril 2005, Electronic journal of oncology

Free Article  

Author(s) : Jawaid Younus, Theodore A Vandenberg

Summary : Tamoxifen has been the standard adjuvant therapy for patients with breast cancer for the last several decades. Several recently completed adjuvant trials using aromatase inhibitors have shown the superiority of these agents over Tamoxifen or placebo, when used in postmenopausal women. The results from these trials present a challenging situation for practicing oncologists with regards to the choice, duration, sequence of therapy, follow up and side effects of aromatase inhibitors. We have discussed various management issues from a practical angle for oncologists to effectively use these agents, with an evidence-based approach.

Keywords : adjuvant therapy, aromatase inhibitor, breast cancer, tamoxifen

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]